Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.

Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, Joint European Cohort Study. · 2008

Read Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. by Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, Joint European Cohort Study. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2658827.txt.

Introduction

Dillner and the Joint European Cohort Study team reported in 2008 how long a negative screening result protects women against advanced cervical cell changes. They pooled seven studies from six European countries, covering 24,295 women. Each woman had tests for the wart virus HPV, which drives cervical cancer, and standard cell checks called cytology.

Six years after a negative virus test, only about 0.27 percent of women had developed severe cell changes or cancer, a very low rate. A negative cell check gave less safety: about 0.97 percent over the same span. Women who passed the cell check but carried the virus saw their risk climb steadily, reaching 10 percent by year six. The authors conclude that virus-based screening every six years is safe, and could replace more frequent cell checks.

Catalog record

CREATORDillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, Joint European Cohort Study.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2658827

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study By Joakim Dillner, Matejka Rebolj, Philippe Birembaut, Karl-Ulrich Petry, Anne Szarewski, Christian Munk, Silvia de Sanjose, Pontus Naucler, Belen Lloveras, Susanne Kjaer, Jack Cuzick, Marjolein van Ballegooijen Published in: The BMJ DOI: 10.1136/bmj.a1754 ABSTRACT Objective To obtain large scale and generalisable data on the long term predictive value of cytology and human papillomavirus (HPV) testing for development of cervical intraepithelial neoplasia grade 3 or cancer (CIN3+). Design Multinational cohort study with joint database analysis. Setting Seven primary HPV screening studies in six European countries. Participants 24 295 women attending cervical screening enrolled into HPV screening trials who had at least one cervical cytology or histopathology examination during follow-up. Main outcome measure Long term cumulative incidence of CIN3+. Results The cumulative incidence rate of CIN3+ after six years was considerably lower among women negative for HPV at baseline (0.27%, 95% confidence interval 0.12% to 0.45%) than among women with negative results on cytology (0.97%, 0.53% to 1.34%)). By comparison, the cumulative incidence rate for women with negative cytology results at the most commonly recommended screening interval in Europe (three years) was 0.51% (0.23% to 0.77%). The cumulative incidence rate among women with negative cytology results who were positive for HPV increased continuously over time, reaching 10% at six years, whereas the rate among women with positive cytology results who were negative for HPV remained below 3%. Conclusions A consistently low six year cumulative incidence rate of CIN3+ among women negative for HPV suggests that cervical screening strategies in which women are screened for HPV every six years are safe and effective. INTRODUCTION Cytological screening has reduced the incidence of cervical cancer in countries with organised screening,1 but in Europe in 1995 there were still an estimated 68 000 incident cases.2 Cytology has limited reproducibility,3 and both meta-analyses and pooled analyses of cross sectional studies have established that tests for human papillomavirus (HPV) have higher sensitivity than cytology in detecting high grade cervical intraepithelial lesions (CIN)4 5 and that combined HPV and cytology testing has high negative predictive values for CIN.6 7 8 Cost effectiveness modelling of screening strategies, however, depends greatly on reliable and generalisable estimates of the longitudinal, long term predictive values of testing. The long term negative predictive value is the main determinant of the safe screening interval to use, a key factor for the cost efficiency of a screening programme. The long term positive predictive value is an important measure of the extent of unnecessary procedures induced by screening, another major factor in evaluations of cost efficiency. As low and moderate grades of CIN often regress, predictive values to be used for modelling should ideally use CIN grade 3 or cancer (CIN3+) as the outcome.9 Several randomised controlled trials are currently being conducted to compare primary screening based on HPV detection with conventional cytology screening.10 11 12 13 14 15 16 Data from these trials indicate that HPV based screening results in detection of more high grade CIN lesions (a higher sensitivity) but a reduced specificity compared with cytology based screening. The randomised trials found that the increased sensitivity for CIN3+ is not merely overdiagnosis as there is a correspondingly lower incidence of CIN3+ in the future,11 12 13 14 further establishing the validity of using CIN3+ as end point in studies of HPV based cervical screening. Most of the cohort studies and the randomised trials, however, have observed only limited numbers of cases of CIN3+ on longer term follow-up, resulting in reduced statistical power for estimating the critical factor for deciding the appropriate screening interval: the rate of CIN3+ among women with negative results at screening. Furthermore, clinical and diagnostic practices vary between European countries, and different studies have often used different methods for evaluation, making meta-analyses difficult. To obtain large scale and generalisable data on long term predictive values for CIN3+, we obtained primary data from seven HPV screening studies in six EU countries, each investigating the predictive value of primary HPV screening for future CIN3+; assessed variability between studies; and estimated the overall long term predictive values for CIN3+. METHODS The seven prospective HPV studies supplied data to a common database for joint statistical analysis. Table 1 provides details of the design of the seven studies, inclusion and exclusion criteria, setting, and location. All studies used routine cytology as currently practised in their country. Table 1 also describes the different HPV tests used for each country. For all studies the people executing either test were unaware of the results of the other test. Comparability and reproducibility of the two main HPV tests used (hybrid capture II and GP5+/6+ polymerase chain reaction) was evaluated with κ statistics.17 Recruitment was consecutive and data collection prospectively planned. [Table: Study characteristics of seven European human papillomavirus (HPV) screening studies] Denmark In 1993-5 women in the general population were enrolled in a prospective cohort study of the clinical course of HPV and cervical neoplasia. They were interviewed and underwent a cervical smear tests for cytology and cervical swabs for detection of HPV DNA with hybrid capture II.18 Each woman’s unique 10 digit personal identification number was linked to the national pathology data bank (a nationwide computerised pathology register containing all cytological and histological diagnoses) to allow follow-up. Data from women with negative results on both tests were supplied to the joint database. Germany: Hannover and Tübingen studies In 1999-2000 women aged ≥30 were invited to the medical universities in Hannover or Tübingen for a prospective cohort study (HAT trial) on HPV screening.6 In Hannover women were followed with colposcopy every 6-12 months if they had a positive result on a hybrid capture 2 test or positive cytology at baseline. Women with negative results on both tests underwent annual cervical smear tests and 5% were referred for colposcopy five years later. In Tübingen, women with negative results on both tests at baseline were followed up with cytology and hybrid capture II test after five years; and if either test result was positive then they were referred for colposcopy. United Kingdom The UK study included women attending routine screening in west London to evaluate HPV based screening in women aged ≥35 during 1994-7.19 DNA analysis was initially performed with the polymerase chain reaction/SHARP system to detect HPV types 16, 18, 31, 33, 54, 51, 52, 56, and 58. Women with positive results on HPV tests or abnormal cytology were referred for colposcopy. The samples were retrospectively analysed with hybrid capture I for the first half of the study and by hybrid capture II for the second half of the study. HPV results reported in our analyses are based on hybrid capture results. All women were followed up with the National Health Service computerised call/recall system, which records all smear tests and their results. In addition, all women were invited to a follow-up visit with HPV test and colposcopy, and 507 out of 2982 attended. France Women who participated in biennial or triennial routine screening in 1997-2002 in Reims, France, were invited to participate in a study to evaluate HPV testing with hybrid capture II in cervical cancer screening.20 All women with abnormal results on

Read the complete text